VitaGraft Kidney's Ability to Differentiate ABMR and IgAN in Kidney Transplant Patients

OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has recently released new data that demonstrates the effectiveness of VitaGraft Kidney in aiding physicians in treating kidney transplant patients with greater precision. The study focused on differentiating between two common causes of premature graft failure: antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN)...